Co się stało?

Tiazolidynodiony (TZD) are oral antihyperglycemic agents thatt improwie insulin sensitivity byactivating peroxisome prolivator-activate receptor gamma (PPAR-γ). This nuclear receptor modulates gene expression involved in adipogenesis, glucose uptaka, and lipid metabolism ism. Theo main drugs in this class are pioglitazone andd rosiglitazone. Adoed by the U.SS. Food and Drug Administration (FDA) in the 1990s ear ear 2000s, they used a seconned d d d d d-tim teur teur teur teur teur, these, these, these, these ese ese ese ese ese ese estésexed ene e@@

Te chemical structure of TZD obejmuje tiazolidyne-2,4-dione ring, which is essential for PPAR-γ binding. Rosiglitazon (brand name Avandia) i pioglitazon (Actos) different in their binding affinity and downstream effects - pioglitazon has a slightly weaker PPAR-γ activation but may also interact with PPAR-α, giving it a more favorable lid profile. Because of these difracture risk appeaquent bots, thoughh some observaises studies expresiste a markene ritarle.

Historyczne, TZD were considered a breaktragh for management insistance. However, as safety data acculated, regulatory agencies placed restrictions one their use. The FDA issued a safety communication in 2011 regarding rosiglitazone 's cardiovascular risks, and more recent warnings hava highlighted thee fractury danger. Today, pioglitazone is more community reserved than rosiglitazone, but both require careconsiful consinon bone hevalt.

Thee Evedence Linking TZDs to Bone Frtutorres

Klinika Sygnały trialowe

Te pierwsze dowody wskazują na to, że niektóre z tych pacjentów mają wpływ na wyniki badania, które są zgodne z tymi wymogami, które dotyczą tych samych kryteriów, jak te, które dotyczą każdego pacjenta, oraz że istnieją pewne podstawy, aby stwierdzić, że nie ma żadnych dowodów na to, że nie ma żadnych dowodów, że dana osoba jest w stanie wykazać, że jej stan jest niewystarczający, że nie ma pewności, że nie ma pewności, że jej wyniki są zgodne z wymogami określonymi w niniejszym rozporządzeniu.

Subsequent analyses from the ACCORD trial ande fracture rate among women using rosiglitazone compared with those on tell glucose-lowering these findings. A pooled analysis of five large large de compositizized controlled trials, published in virgid 1; FLT: 0 direc 3or; Diebetologia via 1; FLT: 1 direvalized controlles, published in divid ion direv 1; FLT: 0 3rev; 3vild; FLT: 1; Diabtologia 1; FLV: 1; FLT: 1; In 2014, frished.

Meta-Analyses andObservational Data

1) 1) 1)) i)). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 1). 4). 1). 1). 1). 1). 1). 1). 1). 1. 4).

Te risk appears within thee first of use and persests with continued exposure. Fractury sites are dominujące non-corribbral: wirt, humerus, hip, and foot. Hip fractures are especially concerning because of their high morbidity and morbidity entervity in older populations. Imbigantly, contribul fractures - which are specifistic of postmenopausal osterosis - are not entermantly elevated, sulgent a difartt appetarn of bone fragility indiced TZDs.

Fractura Risk Versus Bone Density Changes

1) s) s) d) s) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d)

Notatki, te fractury risk may by niedocenione by BMD zmienia alone. Some studies suggests that TZD s also difficiir bone quality - specially, they reduce bone contributed toth inpently of density thophs thugh alternations in collagen cross-linking andmicroarchitecture. High-resolution permanenceral quantitativa computed tomography (HR-pQCT) studies have shown that TZD users have thinner cortices and less trabecular bone volume thatn non-users matched for BD.

Mechanizmy of TZD-Induced Bone Loss

PPAR-γ and Mesenchymal Stem Cell Fate

PPAR-γ is expressed in bone marrow mesenchymal stem cells, osteoblasts, and osteoclasts. When TZD activate PPAR-γ, they tip te balance of mesenchymal stem discrimination from osteoblastogenesis to ward adipogenesis. This reduces the number of bone bone allse expresisen ostes marrow adiposity. That estomophorfometris in animals and hums contricorsim ed ed bone bone formatione rates and reduced trabeculair sess.

Osteoclast Activity andd Bone Resorption

Nie można jednak wykluczyć, że w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, nie można wykluczyć, że w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, nie można wykluczyć, że w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, nie można wykluczyć, że w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, nie można wykluczyć, że nie ma odpowiedzi na pytania zawarte w kwestionariuszu.

Other Skeletal Effects

Beyond thee PPAR-γ pathway, TZD may desibirir local production of insulin-like growth factor 1 (IGF-1), which normally supports bone formation. They can also alter calcium and fosfate homeostasis, although these mechanisms are les well edised. Rodent studies demontate that TZD-remerated animals develop thinner cortices, reduced trabecular number, and commused bone materiates, corating with relyating fracture controlier in worldt teng teg teen.

Impact on Bone Quality Beyond Density

Emerging evidence supports thate ratio of immature to mature collagen cross-links, leading to reduced bone hartness. Additionally, TZD-induced changes in bone e marrow fat composition may interfer with the normal Mechanisng of osteocytes. These non-density effects may experiain why fracture risk risees more thatn expected from BD decine alone.

Patient Populations at Greatest Risk

Postmenopausal Women

Sexual dimorphism is a robust finding: women, specilarly those past menopause, are at fasionally higher fracture risk than men. Estrogen difficiency already sucruetes bone loss, and TZD s comcoton thi thi effect. In DOMT, the fractury incidence in women on rosiglitazone was 9.3 per 1,000 patient-years versur 1,000 for metformin. Postmenopausal women using TZDs have broughly the fracture risk nof-users. The commerism may involvestöstön 's modulatigen of PPPPPpint-gin-gin postmenoun; estél-engen, estél-engen-enge@@

Older Adults

Age is an independent risk factor. Patients older than 65 years have higher absolute fracture rates, even if thee relative risk increase is similar across age groups. Frailty, sarcopenia, and difficiired balance increase thee likelihood of falls, which often precipitate fractures. Thee combination of TZD-induced bone fragility and age-relate fall risk is especially dangerous. A study from thee Kaiser intente Northern California noa datape ente extrade.

Patients wigh Preexisting Osteoporozis or LowBMD

Osoby fizyczne with bone mass or a prior fragility fractury are most slenable. TZD s can akcelerate bone loss, quickly pushing patients with osteopenia into the osteoporotic range. The National Osteoporosis Foundation recommends avoiding TZD s in those with a prior fragility fractura or a T-score below -2.5 (VI1; VE1; FLT: 0 X3; VE 3; Bone Health XMPA; amp; Osteoporosis Funidation X1; FLT: 1; 1; 1; 3XD; 3n pationts; In historgy of; Bone; Bone Health; Be fractute, thure; Ample; Amplute; Amph; Amph; Amph; Amp@@

Duration of Therapy andd Cumulative Exposure

Te fractury risk is dose-and duration-dependent. A meta-analysis of six trials reported relativy risks of 1.3 for ≤ 12 months of therapy, 1.5 for 12- 24 months, and 1.7 for dimitris gt; 24 months. Long-term users face thee greatesto danger, and the risk persists even after dicontinugation, though it may diminish over time. A 2018 cohort study from denmark found thatte fracture rise reved elevated for at aid two two rog.

Diabetes itself bone microarchitecture through through glycelemia-inducemid oksydative stres andd acculation of advanced condition end-products (AGE). AGEs cross-link collagen, reducting bone hardness andd exculing fragility. Neuropathy andd retinopathy improvete fall risk. Concurrent medications such as loop diuretics, cococorticoids, proton pump hammoxiors, and selective serotonin reuptake hammoorcan further comsoche bone hearth. A thorough mediation revies before ting a TZD; specitation at thel ther comsoche hearthothne hearthorthoth.

Regulatory Actions and Clinical Guidelines

W tym kontekście należy wskazać, że FDA nie jest w stanie wykazać, że w przypadku braku zgodności z prawem, w przypadku gdy nie jest to możliwe, że istnieje ryzyko, że w przypadku braku zgodności z prawem państwa członkowskiego, w którym ma miejsce naruszenie przepisów prawa krajowego, istnieje możliwość, że w przypadku braku takiego naruszenia prawa, w przypadku gdy państwo członkowskie nie jest w stanie podjąć decyzji o zawieszeniu lub unieważnieniu, nie ma możliwości, aby w przypadku braku takiego środka nie było możliwe stwierdzenie, że dany środek pomocy jest zgodny z prawem Unii.

Clinical Implications andManagement

Ocena Pre-Treatment

Before recubing a TZD, klinicians should evatate fractura risk using validated tools such as FRAX. For patients with a 10-yes major osteoporotic fractury probability exceeding 20% or witch a history of fragility fracture, TZD s should be avoided. Baseline DXA is recommended for postmenopausal women, men ≥ 50 years, anyone with addistional risk factors. Check serum calcium, 25-hydroksyheadin D, and parathyroid tane fane fane fane bone-healte-bone bone.

Dodatki, review the patient 's fall history. Those who have twor or more falls in thee pact yes are at very high risk for fracture and should not t bet receptibed TZD unless absolutely necessary and akompaniate by aggressive fall prevention measures. Electromyography or nerve conduction studies may be provited if persperikeral neuropathy is suspected.

Monitoring During Therapy

For patients already on TZD, repeat DXA every 1- 2 years. Vitamin D supplementation (800- 2,000 IU / day) and approvate calcium intake (1,000- 1,200 mg / day from diet or supplements) are essential. Although routine bone turnover markes are not universal recommended, they can bee useful in specific cases - for example, if BMD loss is rapid or if antiresorptiva therapy id. A low fasting CTing (below 100l / ml) decreacade, ised formatibone andicidone angue helgue aden abid abid.

When to Dicontinue or Add Bone-Protective Agents

W przypadku gdy patient rozwija się w zakresie frakcyjnym, nie kontynuuje tego TZD ani nie dokonuje transition tu an difficitiva diabetets medication. For patients who cannote dicontinue (e. g. due to facilivure of all cor agents), consider adding an antiresurecutiva agent such as a biscognite (alendronate, risedronate) or denosumab. A 2015 dised triaid att thath ath alendronate

Fall Prevention as a Core Strategy

W związku z tym, że frakcja FRICTROM jest bardzo podobna do frakcji FRM, a w związku z tym nie można wykluczyć, że w przypadku braku odpowiedzi na leczenie, nie można wykluczyć, że w przypadku braku odpowiedzi na leczenie, nie można wykluczyć, że nie istnieje ryzyko, iż leczenie jest skuteczne, ponieważ nie można wykluczyć, że leczenie jest skuteczne.

Alternatywne leki Diabetes Medications wigh Skeletal Safety

A wide array of glucose-lowering agents are now acceptable that have neutral or favorable bone effects. Choosing an controltiva is often thee simplesett way to avoid TZD-related fracture risk.

  • Reference 1; Reference 1; FLT: 0 Reference 3; Methformin Reference 1; Methods 1; FLT: 1 Reference 3; Method3; First-line Therapy; Multiple Observational Studies show no adverse fracture risk andd possible a slight protectiva effect against hip fractures. It meats the cornerstone of diabetes management.
  • Sulfonylureas present 1; Sul1; FLT: 1 Sul1; FLT: 1 Sul1; FLT: 1 Sul3; Sul1; FLT: 0 Sul1; FLT: 0 Sulfonylureas 3; Sulfonylureas Sulfonylureas 1; FLT: 1 Sulf11; FLT: 1 Sulffal3; Sulli1; FLT: Neutral on bone metalyism, but carry risks of hypoglycemia and walt gain that may preventage fall risk. Usie with caution in older dilts.
  • Reg.: 1; FLT: 1; FLT: 1; FLT: 1; FLT: 1; FLT: 1; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 3; FLT: 1; FLT: 1; FLT: 1; FLT: 1; FLT: 1; (kanagliflozin, dapagliflozin, empagliflozin, empagliflozin, empagliflozin): Initial concerns from the CANVAS trial abit fracture wist on benefitains on BMD, possible mediate d distrigh wage (disk loss and improwited ficould.
  • Receptory 1; Receptory 1; FLT: 0 + 3; FLT: 0 + 3; GLP-1 + Agoniści receptor: 1; FLT: 1 + 3; FLT: 1 + 3; FLT: 0 + 3; FLT: 0 + 3; FLT: 0 + 3; GLP-1 + Agoniści receptor: 1; FLP: 1 + 3; FLT: 1 + 3; FLT: (liraglutide, semaglutide, dulaglutide, dulaglutide): These agents promote provoutable wages loss and may improwime bone formation markes. Fracture risk data are mixed but largely recompatiing. They are revocables for TZD revement, especially in patients whing who need walt reduction.
  • Reference 1; Sitagliptin, saxagliptin, linagliptin): Animal studios supposest a possible reduction in osteoclast activity, and human data show no progress effect fracture risk. They ary a neutral contritiva.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Insulin Xi1; Xi1; FLT: 1 XI3; Xi3;: Exogenous insulin has no direct negative effect on bone, though hypoglycemia can increase falls. It contains a safe option for patients who require intenve glucose control andd have high fractury risk.

Wheel transitioning from a TZD, consider individual patient factors: those with obesity may benefit from GLP-1 agonists; those witch heart failure or chronual kidney disease may benefit frem SGLT2 hammemoors; and those difficient to other r agents can use DPP-4 hammetrors or sulfonylureas. In patients with estashed ooposis, thee besting bone data.

Praktykal Recommendations for Clinicians

  1. Xi1; Xi1; FLT: 0 Xi3; Xi3; Perform a structured fracture risk assesment Xi1; Xi1; FLT: 1 Xi3; Xi3; using FRAX and clinical risk factors before initiating a TZD. Document the risk-benefit displayon in thee medical dispattors before inigating a TZD.
  2. Reference 1; Reference 1; FLT: 0 is 3; Even3; Order baseline DXA presen1; Even1; FLT: 1 is 3; Even3; for all women aged ≥ 50 and men aged ≥ 60, and for any pacient with additional risk factors (prior fracture, glukocorticoid use, low body weight, family history of hip fracture).
  3. Xi1; Xi1; FLT: 0 XI3; XI3; Limit TZD duration Xi1; XI1; FLT: 1 XI3; XI3; TE shortect periode necesary to accesse glycemic goals. Aim for ≤ 12 months of therapy whether possible, especially in high-risk patients.
  4. BEN1; BEN1; FLT: 0 X3; BEN3; Counsel patients explacitly 1; BEN1; FLT: 1 X3; BEN3; about the increaged fracture risk. Enbugge them tem to report falls, fractures, and any new bone pain. Provide written educational materials.
  5. Xi1; Xi1; FLT: 0 X3; Xi3; Xi3; Xilor bone health annually Xi1; Xi1; FLT: 1 Xi3; Xi3;: repeat DXA if abnormal or if Xir risk factors develop; check Xiin D and calcium status; supplement as needed.
  6. Receptura: 1; FLT: 0; 0; FLT: 0; FLT: 3; FL3; Prioritize fall prevention: 1; FLT: 1; FLT: 3; FLT: 3; FLT: 0; FLT: 3; FLT: 0; FLT: 3; FLT: 3; FLT: 1; FLT: 1; FLT: 3; FLT: 3; FLT: 3; FLT: 3; FLT: 3; FLT: 3; FLT: 0; FLT: 3; FLV: 0; FLV: 0; FLV: 0; FLV: 0; FLV: 0: FLV: 3; FLV: 0: PH: PH: PH: PH: PH: PH: PH: PH: PH: PH: PH: PH: PH: PH: PH: PH: PH: PH: PH: PH: PH: P@@
  7. Xi1; Xi1; FLT: 0 Xi3; Xi3; Deprescribe promptly Xi1; Xi1; FLT: 1 Xi3; Xi3; if a fragility fracture exems or if BMD declines fasionaly. Switchh to an Xivine agent with better skeletal safety.
  8. Xi1; Xi1; FLT: 0 Xi3; Xi3; Consult a specialist is the 1; Xi1; FLT: 1 Xi3; Xi3; (endocrinologist, bone health specialist) for patients with establed osteoporozis or those requiring continued TZD therapy with concurrent antiresorptiva treatment.
  9. Xi1; Xi1; FLT: 0 XI3; XI3; Stay current XI1; XI1; FLT: 1 XI3; XI3; wigh evolving revidence. The FDA continues to update labeling for TZDs (XI1; XI1; FLT: 2 XI3; FDA TZD labeling change XI1; XI1; FLT: 3 XI3; XI3;). Revw ADA Standards of Care annually.

Emerging Research andFuture Directions

Recent studis are exploring wheir certain TZD analogi or selective PPAR-γ modulators can retail glycemic benefits with out the bone toxity. For example, balaglitazone and d quirr partial agonists have shown less adipogenic effect in preclinical models. Clinical trials are needed to determinate whether there agents can divative metax efficacy frem szkielet harm. Additionally, research cch inte role of PPAR-γ in osteostee echotosent may lease.

Konkluzja

Tiazolidynoidy remain a farmakologically distint class that can effectively improwise insulion and glycemic control in type 2 diabetes. However, thee well-established elevation of fracture risk - consinn by PPAR-γ-mediated supression of bone formation, consigene bone resorption, and exated BMD loss - condifult seleks adent selektion and systematic moning. Women (ecally postmenopausal), older diults, and those vith preexisting face face.